Literature DB >> 25853764

PML in a patient without severe lymphocytopenia receiving dimethyl fumarate.

Dennis J Nieuwkamp1, Jean-Luc Murk, Bob W van Oosten, Charlotte H P Cremers, Joep Killestein, Marco C Viveen, Wim Van Hecke, Daphne W Frijlink, Mike P Wattjes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25853764     DOI： 10.1056/NEJMc1413724

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  58 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 3.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

4.  [Current immunotherapy of multiple sclerosis].

Authors:  F Paul; K Ruprecht
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 5.  Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy.

Authors:  Ralf A Linker; Aiden Haghikia
Journal:  Ther Adv Chronic Dis       Date:  2016-06-10       Impact factor: 5.091

6.  Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression.

Authors:  Jessie Grewal; Poorvi Dalal; Michelle Bowman; Behiye Kaya; José Javier Otero; Jaime Imitola
Journal:  J Neurovirol       Date:  2016-06-06       Impact factor: 2.643

7.  [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

8.  Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors:  Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal:  J Neurol       Date:  2016-05-18       Impact factor: 4.849

Review 9.  Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors:  J Nicholas Brenton; Brenda L Banwell
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 10.  Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

Authors:  Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik
Journal:  Ann Neurol       Date:  2015-07-31       Impact factor: 10.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.